Cidara Therapeutics Completes Acquisition by Merck Subsidiary, Delists from Nasdaq

summarizeSummary

Cidara Therapeutics announced the completion of its acquisition by Merck Sharp & Dohme LLC, with the company becoming a wholly-owned subsidiary and its common stock being delisted from Nasdaq.

check_boxKey Events

• Acquisition Completed

  Merck Sharp & Dohme LLC's subsidiary, Caymus Purchaser, Inc., completed the tender offer and subsequently merged with Cidara Therapeutics, making it a wholly-owned subsidiary.

• Tender Offer Details

  The tender offer for common shares was priced at $221.50 per share and Series A preferred shares at $15,505.00 per share. Approximately 88.3% of total voting shares were validly tendered.

• Delisting from Nasdaq

  Cidara Therapeutics has requested Nasdaq to halt trading and delist its common shares, and intends to deregister its shares with the SEC, terminating its reporting obligations.

• Change in Control and Leadership

  A change of control occurred, and the company's board of directors and officers were replaced by those of the acquiring subsidiary.

auto_awesomeAnalysis

This 8-K filing confirms the completion of the acquisition of Cidara Therapeutics by Merck Sharp & Dohme LLC, a significant event that fundamentally alters the company's future. Cidara Therapeutics is now a wholly-owned subsidiary, ceasing to be an independent public entity. For investors, this means their shares have been converted into cash at the offer price, and the stock will no longer trade on Nasdaq. The delisting and deregistration mark the definitive end of Cidara Therapeutics' public life, making this a critical, thesis-altering event for any previous shareholders.